Virus-specific T-cell therapy in solid organ transplantation.
This article reviews the current state of T-cell therapy as therapeutic option for virus-associated diseases against the background of the most common viral complications and their standard treatment regimens after SOT. The available data of clinical T-cell trials in SOT are summarized. References to the hematopoietic stem cell transplantation are made if applicable data in SOT are not available and their content was considered likewise valid for cell therapy in SOT. Moreover, aspects of different manufacturing approaches including beneficial product characteristics and the importance of GMP compliance are addressed.
Department of Nephrology and Internal Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.|Berlin-Brandenburg Center for Regenerative Therapy (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany.
Andy
A
Roemhild
Department of Nephrology and Internal Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.|Berlin-Brandenburg Center for Regenerative Therapy (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany.
Petra
P
Reinke
D000257:Adenoviridae Infections / Q000150:complications; D000293:Adolescent; D000328:Adult; D000368:Aged; D018951:Antigens, CD20 / Q000378:metabolism; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000150:complications; D018450:Disease Progression; D020031:Epstein-Barr Virus Infections / Q000150:complications; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive; D007223:Infant; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation; D013601:T-Lymphocytes / Q000166:cytology*; D014777:Virus Diseases / Q000517:prevention & control*
D018951:Antigens, CD20; D000998:Antiviral Agents; D007166:Immunosuppressive Agents
Epstein-Barr virus; T-cell therapy; good manufacturing practices; human cytomegalovirus; solid organ transplantation; virus-specific